Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 59 entries
Sorted by: Best Match Show Resources per page
Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.

Journal of pharmaceutical sciences

Wyska E, Mager DE, Krzyzanski W.
PMID: 12820148
J Pharm Sci. 2003 Jul;92(7):1438-54. doi: 10.1002/jps.10407.

The basic indirect response models are described by several pharmacodynamic parameters of which IC(50) (drug concentration eliciting 50% of the maximum inhibition) and SC(50) (drug concentration eliciting 50% of the maximum stimulation) are not readily derived from the response...

Cite
Wyska E, Mager DE, Krzyzanski W. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci. 2003;92(7):1438-54doi: 10.1002/jps.10407.
Wyska, E., Mager, D. E., & Krzyzanski, W. (2003). Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. Journal of pharmaceutical sciences, 92(7), 1438-54. https://doi.org/10.1002/jps.10407
Wyska, Elzbieta, et al. "Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data." Journal of pharmaceutical sciences vol. 92,7 (2003): 1438-54. doi: https://doi.org/10.1002/jps.10407
Wyska E, Mager DE, Krzyzanski W. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci. 2003 Jul;92(7):1438-54. doi: 10.1002/jps.10407. PMID: 12820148.
Copy Download .nbib Format: NLM
Concentration-effect and dose-response relations in clinical pharmacology.

British journal of clinical pharmacology

Aronson JK.
PMID: 17311674
Br J Clin Pharmacol. 2007 Mar;63(3):255-7. doi: 10.1111/j.1365-2125.2007.02871.x.

No abstract available.

Cite
Aronson JK. Concentration-effect and dose-response relations in clinical pharmacology. Br J Clin Pharmacol. 2007;63(3):255-7doi: 10.1111/j.1365-2125.2007.02871.x.
Aronson, J. K. (2007). Concentration-effect and dose-response relations in clinical pharmacology. British journal of clinical pharmacology, 63(3), 255-7. https://doi.org/10.1111/j.1365-2125.2007.02871.x
Aronson, Jeffrey K. "Concentration-effect and dose-response relations in clinical pharmacology." British journal of clinical pharmacology vol. 63,3 (2007): 255-7. doi: https://doi.org/10.1111/j.1365-2125.2007.02871.x
Aronson JK. Concentration-effect and dose-response relations in clinical pharmacology. Br J Clin Pharmacol. 2007 Mar;63(3):255-7. doi: 10.1111/j.1365-2125.2007.02871.x. PMID: 17311674; PMCID: PMC2000728.
Copy Download .nbib Format: NLM
Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?.

British journal of clinical pharmacology

Baber NS.
PMID: 15948928
Br J Clin Pharmacol. 2005 Jun;59(6):660-2. doi: 10.1111/j.1365-2125.2005.02427.x.

No abstract available.

Cite
Baber NS. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?. Br J Clin Pharmacol. 2005;59(6):660-2doi: 10.1111/j.1365-2125.2005.02427.x.
Baber, N. S. (2005). Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?. British journal of clinical pharmacology, 59(6), 660-2. https://doi.org/10.1111/j.1365-2125.2005.02427.x
Baber, N S. "Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?." British journal of clinical pharmacology vol. 59,6 (2005): 660-2. doi: https://doi.org/10.1111/j.1365-2125.2005.02427.x
Baber NS. Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children?. Br J Clin Pharmacol. 2005 Jun;59(6):660-2. doi: 10.1111/j.1365-2125.2005.02427.x. PMID: 15948928; PMCID: PMC1884861.
Copy Download .nbib Format: NLM
Correct date for Paracelsus.

The American journal of clinical nutrition

Colombani P.
PMID: 16332673
Am J Clin Nutr. 2005 Dec;82(6):1357. doi: 10.1093/ajcn/82.6.1357.

No abstract available.

Cite
Colombani P. Correct date for Paracelsus. Am J Clin Nutr. 2005;82(6):1357doi: 10.1093/ajcn/82.6.1357.
Colombani, P. (2005). Correct date for Paracelsus. The American journal of clinical nutrition, 82(6), 1357. https://doi.org/10.1093/ajcn/82.6.1357
Colombani, Paolo. "Correct date for Paracelsus." The American journal of clinical nutrition vol. 82,6 (2005): 1357. doi: https://doi.org/10.1093/ajcn/82.6.1357
Colombani P. Correct date for Paracelsus. Am J Clin Nutr. 2005 Dec;82(6):1357. doi: 10.1093/ajcn/82.6.1357. PMID: 16332673.
Copy Download .nbib Format: NLM
Quick lessons on environmental nanotech.

Nature nanotechnology

Toumey C.
PMID: 26139139
Nat Nanotechnol. 2015 Jul;10(7):566-7. doi: 10.1038/nnano.2015.144.

No abstract available.

Cite
Toumey C. Quick lessons on environmental nanotech. Nat Nanotechnol. 2015;10(7):566-7doi: 10.1038/nnano.2015.144.
Toumey, C. (2015). Quick lessons on environmental nanotech. Nature nanotechnology, 10(7), 566-7. https://doi.org/10.1038/nnano.2015.144
Toumey, Chris. "Quick lessons on environmental nanotech." Nature nanotechnology vol. 10,7 (2015): 566-7. doi: https://doi.org/10.1038/nnano.2015.144
Toumey C. Quick lessons on environmental nanotech. Nat Nanotechnol. 2015 Jul;10(7):566-7. doi: 10.1038/nnano.2015.144. PMID: 26139139.
Copy Download .nbib Format: NLM
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.

Clinical and translational science

Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M.
PMID: 26918865
Clin Transl Sci. 2016 Apr;9(2):74-88. doi: 10.1111/cts.12390. Epub 2016 Mar 30.

A number of drivers and developments suggest that microdosing and other phase 0 applications will experience increased utilization in the near-to-medium future. Increasing costs of drug development and ethical concerns about the risks of exposing humans and animals to...

Cite
Burt T, Yoshida K, Lappin G, et al. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. Clin Transl Sci. 2016;9(2):74-88doi: 10.1111/cts.12390.
Burt, T., Yoshida, K., Lappin, G., Vuong, L., John, C., de Wildt, S. N., Sugiyama, Y., & Rowland, M. (2016). Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. Clinical and translational science, 9(2), 74-88. https://doi.org/10.1111/cts.12390
Burt, T, et al. "Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development." Clinical and translational science vol. 9,2 (2016): 74-88. doi: https://doi.org/10.1111/cts.12390
Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. Clin Transl Sci. 2016 Apr;9(2):74-88. doi: 10.1111/cts.12390. Epub 2016 Mar 30. PMID: 26918865; PMCID: PMC5351314.
Copy Download .nbib Format: NLM
[Application of nonlinear regression model to sigmoid dose-response relationship in pharmacological studies].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Sakiyama Y, Ohashi K, Takahashi Y.
PMID: 18854620
Nihon Yakurigaku Zasshi. 2008 Oct;132(4):199-206. doi: 10.1254/fpj.132.199.

No abstract available.

Cite
Sakiyama Y, Ohashi K, Takahashi Y. [Application of nonlinear regression model to sigmoid dose-response relationship in pharmacological studies]. Nihon Yakurigaku Zasshi. 2008;132(4):199-206doi: 10.1254/fpj.132.199.
Sakiyama, Y., Ohashi, K., & Takahashi, Y. (2008). [Application of nonlinear regression model to sigmoid dose-response relationship in pharmacological studies]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 132(4), 199-206. https://doi.org/10.1254/fpj.132.199
Sakiyama, Yojiro, et al. "[Application of nonlinear regression model to sigmoid dose-response relationship in pharmacological studies]." Nihon yakurigaku zasshi. Folia pharmacologica Japonica vol. 132,4 (2008): 199-206. doi: https://doi.org/10.1254/fpj.132.199
Sakiyama Y, Ohashi K, Takahashi Y. [Application of nonlinear regression model to sigmoid dose-response relationship in pharmacological studies]. Nihon Yakurigaku Zasshi. 2008 Oct;132(4):199-206. doi: 10.1254/fpj.132.199. Japanese. PMID: 18854620.
Copy Download .nbib Format: NLM
An examination of the Environmental Protection Agency risk assessment principles and practices: a brief commentary on section 4.1.3 of the EPA March 2004 Staff Paper.

Human & experimental toxicology

Mundt KA.
PMID: 16459710
Hum Exp Toxicol. 2006 Jan;25(1):19-21. doi: 10.1191/0960327106ht580oa.

The US Environmental Protection Agency (EPA) recently issued a Staff Paper that articulates current risk assessment practices. In section 4.1.3, EPA states, "... effects that appear to be adaptive, non-adverse, or beneficial may not be mentioned." This statement may...

Cite
Mundt KA. An examination of the Environmental Protection Agency risk assessment principles and practices: a brief commentary on section 4.1.3 of the EPA March 2004 Staff Paper. Hum Exp Toxicol. 2006;25(1):19-21doi: 10.1191/0960327106ht580oa.
Mundt, K. A. (2006). An examination of the Environmental Protection Agency risk assessment principles and practices: a brief commentary on section 4.1.3 of the EPA March 2004 Staff Paper. Human & experimental toxicology, 25(1), 19-21. https://doi.org/10.1191/0960327106ht580oa
Mundt, K A. "An examination of the Environmental Protection Agency risk assessment principles and practices: a brief commentary on section 4.1.3 of the EPA March 2004 Staff Paper." Human & experimental toxicology vol. 25,1 (2006): 19-21. doi: https://doi.org/10.1191/0960327106ht580oa
Mundt KA. An examination of the Environmental Protection Agency risk assessment principles and practices: a brief commentary on section 4.1.3 of the EPA March 2004 Staff Paper. Hum Exp Toxicol. 2006 Jan;25(1):19-21. doi: 10.1191/0960327106ht580oa. PMID: 16459710.
Copy Download .nbib Format: NLM
Proof of concept and dose estimation with binary responses under model uncertainty.

Statistics in medicine

Klingenberg B.
PMID: 19012269
Stat Med. 2009 Jan 30;28(2):274-92. doi: 10.1002/sim.3477.

This article suggests a unified framework for testing Proof of Concept (PoC) and estimating a target dose for the benefit of a more comprehensive, robust and powerful analysis in phase II or similar clinical trials. From a pre-specified set...

Cite
Klingenberg B. Proof of concept and dose estimation with binary responses under model uncertainty. Stat Med. 2009;28(2):274-92doi: 10.1002/sim.3477.
Klingenberg, B. (2009). Proof of concept and dose estimation with binary responses under model uncertainty. Statistics in medicine, 28(2), 274-92. https://doi.org/10.1002/sim.3477
Klingenberg, B. "Proof of concept and dose estimation with binary responses under model uncertainty." Statistics in medicine vol. 28,2 (2009): 274-92. doi: https://doi.org/10.1002/sim.3477
Klingenberg B. Proof of concept and dose estimation with binary responses under model uncertainty. Stat Med. 2009 Jan 30;28(2):274-92. doi: 10.1002/sim.3477. PMID: 19012269.
Copy Download .nbib Format: NLM
Design of experiments for the precise estimation of dose-response parameters: the Hill equation.

Journal of theoretical biology

Bezeau M, Endrenyi L.
PMID: 3657186
J Theor Biol. 1986 Dec 21;123(4):415-30. doi: 10.1016/s0022-5193(86)80211-9.

Optimal experimental designs were evaluated for the precise estimation of parameters of the Hill model. The optimally effective designs were obtained by using the criterion of D-optimization. For the Hill model, optimal designs replicate 3 sampling points. These points...

Cite
Bezeau M, Endrenyi L. Design of experiments for the precise estimation of dose-response parameters: the Hill equation. J Theor Biol. 1986;123(4):415-30doi: 10.1016/s0022-5193(86)80211-9.
Bezeau, M., & Endrenyi, L. (1986). Design of experiments for the precise estimation of dose-response parameters: the Hill equation. Journal of theoretical biology, 123(4), 415-30. https://doi.org/10.1016/s0022-5193(86)80211-9
Bezeau, M, and Endrenyi, L. "Design of experiments for the precise estimation of dose-response parameters: the Hill equation." Journal of theoretical biology vol. 123,4 (1986): 415-30. doi: https://doi.org/10.1016/s0022-5193(86)80211-9
Bezeau M, Endrenyi L. Design of experiments for the precise estimation of dose-response parameters: the Hill equation. J Theor Biol. 1986 Dec 21;123(4):415-30. doi: 10.1016/s0022-5193(86)80211-9. PMID: 3657186.
Copy Download .nbib Format: NLM
Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?.

Journal of pharmaceutical sciences

Dutta S, Matsumoto Y, Ebling WF.
PMID: 8683454
J Pharm Sci. 1996 Feb;85(2):232-9. doi: 10.1021/js950067y.

Many drug concentration-effect relationships are described by the nonlinear sigmoid E(max) model. Clinical considerations frequently limit the magnitude of effect intensity that may be produced; the most pronounced effect intensity may be considerably below E(max). We have tested and...

Cite
Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?. J Pharm Sci. 1996;85(2):232-9doi: 10.1021/js950067y.
Dutta, S., Matsumoto, Y., & Ebling, W. F. (1996). Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?. Journal of pharmaceutical sciences, 85(2), 232-9. https://doi.org/10.1021/js950067y
Dutta, S, et al. "Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?." Journal of pharmaceutical sciences vol. 85,2 (1996): 232-9. doi: https://doi.org/10.1021/js950067y
Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?. J Pharm Sci. 1996 Feb;85(2):232-9. doi: 10.1021/js950067y. PMID: 8683454.
Copy Download .nbib Format: NLM
Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes.

Toxicology and applied pharmacology

Strigun A, Wahrheit J, Beckers S, Heinzle E, Noor F.
PMID: 21320520
Toxicol Appl Pharmacol. 2011 Apr 15;252(2):183-91. doi: 10.1016/j.taap.2011.02.008. Epub 2011 Feb 12.

Along with hepatotoxicity, cardiotoxic side effects remain one of the major reasons for drug withdrawals and boxed warnings. Prediction methods for cardiotoxicity are insufficient. High content screening comprising of not only electrophysiological characterization but also cellular molecular alterations are...

Cite
Strigun A, Wahrheit J, Beckers S, et al. Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicol Appl Pharmacol. 2011;252(2):183-91doi: 10.1016/j.taap.2011.02.008.
Strigun, A., Wahrheit, J., Beckers, S., Heinzle, E., & Noor, F. (2011). Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicology and applied pharmacology, 252(2), 183-91. https://doi.org/10.1016/j.taap.2011.02.008
Strigun, Alexander, et al. "Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes." Toxicology and applied pharmacology vol. 252,2 (2011): 183-91. doi: https://doi.org/10.1016/j.taap.2011.02.008
Strigun A, Wahrheit J, Beckers S, Heinzle E, Noor F. Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicol Appl Pharmacol. 2011 Apr 15;252(2):183-91. doi: 10.1016/j.taap.2011.02.008. Epub 2011 Feb 12. PMID: 21320520.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 59 entries